Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oclassen Pharmaceuticals

Executive Summary

Granted exclusive worldwide license from Memorial Sloan-Kettering to develop and market two fluorinated pyramidine antiviral agents -- FIAC (fluoro-iodo-arabinosylcytosine) and FIAU (fluori-iodo-arabinosyluriacil). FIAC, which can be administered both orally and intravenously, will initially be developed for cytomegalovirus infections in AIDS patients. FIAU has already been studied in about 100 patients under a development agreement with Bristol-Myers that was discontinued in 1985. Oclassen's clinical studies are scheduled to begin within six months.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS014380

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel